onc brain

The longer read

The document's central move is to tie the nodal target to diagnostic evidence rather than to anatomy. Nodal GTV is defined by biopsy or focal PET uptake above blood pool, doubt resolves toward inclusion, and a PET-positive node with a negative EBUS/EUS stays in the GTV because endosonographic false negatives are high. Only a clear benign biopsy explanation or a negative mediastinoscopy licenses omission. That is a deliberate asymmetry: the panel prefers the larger volume that a false-positive PET produces over the geographic miss that a false-negative sample produces. For a radiation oncologist whose pulmonology colleague reports a negative EBUS on an avid station, this is the clause that settles the argument at the contouring workstation.

Elective nodal irradiation is handled in the same spirit. Hilum and neighbouring stations are optional, uninvolved gaps between involved stations are optional, and anything further is discouraged. The evidence offered for the station-based CTV option is that large multicentre trials used it without unacceptable out-field mediastinal recurrence. Those trials are not named in the excerpt, and the claim is a reassurance that failure was acceptable, not a comparison against a wider volume. The two nodal CTV options, whole involved station versus 5–8 mm geometric expansion, sit side by side with no preference, which tells the reader the committee could not resolve that question; the choice stays local, with the oesophagus as the usual constraint.

The induction-chemotherapy rule splits primary and nodes. The primary GTV follows current post-chemo CT with pre-chemo imaging considered, while the nodal GTV keeps every pre-chemo involved node or station even after radiographic disappearance. The logic is coherent: primary shrinkage is visible and contourable, nodal sterilisation is not verifiable on imaging. It does commit the reader to treating stations that may be clear, and the document offers no failure-pattern data to show what that buys.

On motion, the panel accepts three policies (an ITV per ICRU 62, mid-ventilation or mid-position with motion folded into the van Herk margin, or gating and tracking with system-specific margins) and asks each department to measure its own residual errors. That is pragmatic, but it means the guideline does not standardise PTV size across centres; the reader inherits the job of measuring setup error. Separate anisotropic margins for primary and nodes are recommended because the two move differently.

Methodologically, the grades come from a questionnaire and committee vote, not from a graded evidence review, and the excerpt reports neither panel size nor per-item agreement. A Mandatory label therefore carries consensus weight, not trial weight, and two Mandatory items may rest on very different evidence. The OAR list is written for conventional or moderate hypofractionation, so the document should not be read across to stereotactic schedules, and PORT is addressed only by analogy plus a fixed CTV of resected involved stations, stump, ipsilateral hilum and stations 4 and 7. Two findings would undercut it: meaningful out-field nodal failure after involved-field contours in PET-staged pts, or evidence that PET-positive, EBUS-negative nodes rarely harbour disease.